As expected, the mice vaccinated with the PSVK-shFcG-GM/B7.1 construct induced the strongest anti-tumor immune response against B16F10-SUR and B16-F10hCGβ cell challenge, using both vaccination strategies. The gene discussed is CD80; the disease is neoplasm.